<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606397</url>
  </required_header>
  <id_info>
    <org_study_id>11071</org_study_id>
    <secondary_id>I1R-FW-GLBB</secondary_id>
    <nct_id>NCT01606397</nct_id>
  </id_info>
  <brief_title>A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes</brief_title>
  <official_title>The Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Escalating Doses of LY2409021 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study drug LY2409021 is being evaluated as a possible treatment for diabetes. The primary&#xD;
      purpose of this study is to help answer the following research questions, and not to provide&#xD;
      treatment for diabetes :&#xD;
&#xD;
        -  The safety of LY2409021 and any side effects that might be associated with it following&#xD;
           4 weeks of doses&#xD;
&#xD;
        -  How long it takes the body to absorb and remove LY2409021 following dosing over 4 weeks&#xD;
&#xD;
        -  How daily dosing of LY2409021 affects blood levels of sugar (glucose), insulin and other&#xD;
           naturally occurring substances before and after a meal&#xD;
&#xD;
        -  How LY2409021 works when given with metformin&#xD;
&#xD;
        -  How daily dosing of LY2409021 affects the cells that produce insulin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with one or more drug related adverse events (AEs) or any serious AEs</measure>
    <time_frame>From first dose of study drug up to discharge (at least 28 days after last dose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration curve (AUC) of LY2409021</measure>
    <time_frame>From first study drug dose to Day 28 post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum concentration (Cmax) of LY2409021</measure>
    <time_frame>From first study drug dose to Day 28 post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting blood glucose level</measure>
    <time_frame>From Day -1 to Day 28 of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in incremental area under the curve (AUC) for glucose</measure>
    <time_frame>From Day -1 to Day 28 of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in homeostasis model assessment of beta cell function (HOMA-B)</measure>
    <time_frame>From baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucagon level</measure>
    <time_frame>From Day -1 to Day 28 of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting insulin level</measure>
    <time_frame>From Day -1 to Day 28 of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting C-peptide level</measure>
    <time_frame>From Day -1 to Day 28 of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucagon-like peptide-1 (GLP-1) level</measure>
    <time_frame>From Day -1 to Day 28 of dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg LY2409021 administered orally once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg LY2409021 administered orally once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg LY2409021 administered orally once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mg LY2409021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 mg LY2409021 administered orally once daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally (capsule)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2409021</intervention_name>
    <description>Administered orally (capsule)</description>
    <arm_group_label>30 mg LY2409021</arm_group_label>
    <arm_group_label>5 mg LY2409021</arm_group_label>
    <arm_group_label>60 mg LY2409021</arm_group_label>
    <arm_group_label>90 mg LY2409021</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be either a male, or a female who cannot become pregnant, who has type 2 diabetes&#xD;
             and is either controlling diabetes through diet and exercise, or taking metformin&#xD;
&#xD;
          -  Have an hemoglobin A1c (HbA1c) value at screening of greater than or equal to 6.5% and&#xD;
             less than or equal to 10.0% on a stable treatment regimen at the time of measurement&#xD;
&#xD;
          -  Have a screening body mass index (BMI) of 20 to 40 kg/m^2 inclusive&#xD;
&#xD;
          -  Have a blood pressure reading at screening of between 90 to 160 millimeters of mercury&#xD;
             (mmHg) (systolic) and 40 to 95 mmHg (diastolic)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have used insulin for diabetic control within 1 year of study entry&#xD;
&#xD;
          -  Have used thiazolidinediones within 3 months, or any other drugs for treatment of&#xD;
             hyperglycemia (except metformin) within 1 month, prior to first planned dosing.&#xD;
             Metformin is acceptable for this study.&#xD;
&#xD;
          -  Have clinically significant coronary artery disease&#xD;
&#xD;
          -  Have clinically significant peripheral vascular disease&#xD;
&#xD;
          -  Have clinical evidence of active diabetic proliferative retinopathy&#xD;
&#xD;
          -  Have known significant autonomic neuropathy as evidenced by urinary retention,&#xD;
             orthostatic hypotension, diabetic diarrhea or gastroparesis&#xD;
&#xD;
          -  Impaired renal function (serum creatinine greater than 115 micromoles/liter [μmol/L]&#xD;
             [1.3 mg/dL] in women, greater than 130 μmol/L [1.5 mg/dL] in men)&#xD;
&#xD;
          -  Have triglycerides greater than 4.5 millimoles per liter (mmol/L) [approximately 400&#xD;
             mg/dL] at screening&#xD;
&#xD;
          -  Were hospitalized for poor control of diabetes (keto-acidotic episode) in the last 6&#xD;
             months&#xD;
&#xD;
          -  Are allergic to LY2409021 or similar drugs&#xD;
&#xD;
          -  Have history or presence of cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine (other than diabetes), hematological, or neurological&#xD;
             disorders capable of significantly altering the absorption, or metabolism or&#xD;
             elimination of drugs or of constituting a risk when taking the study medication or&#xD;
             interfering with the interpretation of data&#xD;
&#xD;
          -  Have used systemic glucocorticoids within 1 month prior to first dosing&#xD;
&#xD;
          -  Have donated 450 mL or more of blood in the last 3 months or have donated any blood&#xD;
             within the last month&#xD;
&#xD;
          -  Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week&#xD;
             (female), or are unwilling to stop alcohol as required by the study restrictions (1&#xD;
             unit = 360 mL of beer, or 150 mL of wine, or 45 mL of spirits)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <last_update_submitted>May 23, 2012</last_update_submitted>
  <last_update_submitted_qc>May 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

